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miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the 
role of miR-155/JARID2 axis in abnormal megakaryopoiesis 
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Key points: 
• Differential gene and miRNA expression analysis in PMF granulocytes identifies 
new biomarkers and putative therapeutic targets 
• Activation of miR-155/JARID2 axis in PMF CD34+ cells results in overproduction of 
megakaryocyte precursors  
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ABSTRACT 
 
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by 
megakaryocyte hyperplasia, bone marrow fibrosis, and abnormal stem cell trafficking. PMF 
may be associated with somatic mutations in JAK2, MPL, or CALR. Previous studies have 
shown that abnormal megakaryocytes play a central role in the pathophysiology of PMF. In 
this work, we studied both gene and microRNA (miRNA) expression profiles in CD34+ 
cells from PMF patients. We identified several biomarkers and putative molecular targets 
such as FGR, LCN2, and OLFM4. By means of miRNA-gene expression integrative 
analysis, we found different regulatory networks involved in the dysregulation of 
transcriptional control and chromatin remodeling. In particular, we identified a network 
gathering several oncomiRs (e.g., miR-155-5p) and targeted genes whose abnormal 
function has been previously associated to myeloid neoplasms, including JARID2, NR4A3, 
CDC42, and HMGB3. Since the validation of miRNA-target interactions unveiled 
JARID2/miR-155-5p as the strongest relationship in the network, we studied the function of 
this axis in normal and PMF CD34+ cells. We showed that JARID2 downregulation 
mediated by miR-155-5p overexpression leads to increased in vitro formation of CD41+ 
megakaryocyte precursors. These findings suggest that overexpression of miR-155-5p 
and the resulting downregulation of JARID2 may contribute to megakaryocyte hyperplasia 
in PMF. 
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INTRODUCTION  
Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are a heterogeneous 
group of clonal hematopoietic stem cell disorders associated with overproduction of 
mature myeloid cells, and include primary myelofibrosis (PMF)1,2. The molecular 
mechanisms underlying MPN pathogenesis were partially disclosed in 2005–2006 with the 
identification of somatic gain-of-function mutations of JAK2 and MPL3,4, after which many 
other mutated genes were found5,6, such as CALR7,8. Despite the fact that the mutational 
landscape of MPNs has been extensively investigated, a comprehensive framework of the 
pathogenetic molecular mechanisms has not been fully elucidated. 
MicroRNAs (miRNAs) are small non-coding RNAs involved in several biological processes 
such as differentiation9, proliferation10, and apoptosis11 through the post-transcriptional 
repression of their targets12. Increasing evidence shows that deregulation of miRNAs plays 
an important role in both solid and hematologic malignancies13,14. In particular, recent 
reports pointed to aberrant miRNA expression in MPNs, and specific miRNA signatures 
that distinguish MPN granulocytes from those of healthy donors have been described15,16. 
However, because MPNs are stem cell-derived disorders, studies on disease mechanisms 
should be focused on a more primitive cell compartment. High-throughput analysis of 
miRNA expression levels in MPN CD34+ cells has been reported in only two studies, 
including a limited number of patients17,18; therefore, our understanding of miRNAs’ 
involvement in MPN pathogenesis is still limited. 
Here, we focused our attention on the molecular mechanisms underlying PMF, the less 
common, and likely the most pathogenetically complex of the MPNs. In order to define the 
role of miRNAs in the pathogenesis of PMF, we obtained both miRNA and gene 
expression profiles (miEP and GEP, respectively) in the same sample of CD34+ cells from 
42 PMF patients and 31 healthy donors. Integration of these profiles allowed us to unveil 
how differentially expressed miRNAs (DEMs) potentially influence the dysregulation of 
several biological processes in PMF by interacting with their target genes. 
In particular, we described a regulatory network involving several upregulated oncomiRs 
and their target mRNAs, including CDC42, HMGB3 and NR4A3 that were previously 
characterized in knockout murine models of myeloproliferative disorders, and the 
chromatin remodeler JARID2.  
We also demonstrated that miR-155-5p affects the in vitro expansion of the 
megakaryocyte (MK) lineage through the modulation of JARID2 expression, suggesting 
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that the miR-155-5p/JARID2 axis might contribute to the abnormal megakaryopoiesis 
typical of PMF.  
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MATERIALS AND METHODS 
 
Patients and samples  
Forty-two patients with a diagnosis of PMF in a typical fibrotic stage of the disease 
according to the World Health Organization (WHO)19 were included in the microarray 
analysis. Their characteristics are reported in Table S1. PMF CD34+ cells were purified 
from peripheral blood (PB). In addition, 16 PB samples and 15 bone marrow (BM) samples 
were collected from normal donors. Moreover, an independent cohort of 36 PMF patients, 
12 healthy donors, and 26 cord blood (CB) samples was selected for validation studies. 
All subjects provided informed written consent, and the study was performed under the 
local Institutional Review Board’s approved protocol. The study was conducted in 
accordance with the Declaration of Helsinki. 
The presence of the JAK2V617F mutation and the allele burden were determined via 
quantitative reverse transcription polymerase chain reaction (qRT-PCR), as previously 
described20. 
 
GEP and miEP integrative analysis 
GEP and miEP were performed on the same RNA preparation using the Affymetrix 
technology (HG-U219 Array Strip and miRNA 2.0 arrays) as detailed in the Supplemental 
Methods. 
Differentially expressed genes (DEGs) and miRNAs (DEMs) were then selected following 
a supervised approach with the ANOVA module included in the Partek GS package. In 
particular, we selected all the probe sets with a fold change contrast ≥2 for DEGs, or ≥1.5 
for DEMs in the pairwise comparison of PMF versus controls, and a false discovery rate 
(FDR) (q-value) <.05.  
To construct the regulatory networks of the functional miRNA-target interactions, in silico 
integrative analysis (IA) was performed by using Ingenuity Pathway analysis software 
(IPA, version 8.6; Ingenuity Systems; Redwood City, CA, http://www.ingenuity.com), which 
combines computationally predicted targets with gene expression data. Briefly, the lists of 
DEMs and DEGs were separately uploaded on the software; then, the putative targets of 
DEMs were identified within the DEG list by microRNA Target Filter, according to at least 
one out of four different databases (TargetScan, miRecords, Tarbase, or Ingenuity expert 
findings); finally, pairs with anti-correlated expression trends were filtered and selected for 
further analysis to build the regulatory networks.  
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Electroporation of CD34+ cells 
The electroporation program of CD34+ cells was based on a previously published 
protocol21, which was optimized to be performed on the 4D-Nucleofector™ System 
(Lonza) (see Supplemental Results). Briefly, each sample was electroporated three times 
once every 24 hours (h) with a mix of three Silencer Select small interfering RNAs 
(siRNAs) targeting human JARID2 (Table S2) (Life Technologies), starting from the day 
after CD34+ cell purification22. For each electroporation, 4×105 CD34+ cells were 
resuspended in 100 µL of P3 Primary Cell Solution (Lonza), containing 3 µg of siRNA mix, 
and pulsed with the program DS112. To exclude non-specific effects caused by interfering 
RNA (RNAi) nucleofection, a sample transfected with a non-targeting siRNA (NegCTR; 
Silencer Select Negative Control #2 siRNA; Life Technologies) was included.  
As described for siRNA transfections, the number of nucleofections and the quantities of 
miRNA mimics/inhibitors were modified from a previously described protocol23 to best fit 
the properties of the second generation of miRNA mimics/inhibitors (Life Technologies). 
Briefly, CD34+ cells were nucleofected twice, once every 24 h, with 3 µg of mirVana™ 
miR-155-5p mimic or mirVana™ miRNA mimic Negative Control #1 (Neg-mimic), by using 
the above-mentioned electroporation protocol DS112. PMF and CB CD34+ cells were 
nucleofected four times, once every 24 h, with 3 µg of mirVana™ miR-155-5p inhibitor or 
mirVana™ miRNA inhibitor Negative Control #1 (NegINH), by using the electroporation 
protocol DS112. 
Cells were analyzed 24 h and 48 h after the last nucleofection for both cell viability and 
JARID2 or miR-155-5p expression.  
 
Statistical analysis  
The SPSS software (StatSoft; Tulsa) was used for statistical analysis of clinical correlation. 
Comparison between groups was performed by using the Student’s t-test, and the chosen 
level of significance was P <.05 with a two-sided test.  
The statistics used for data analysis in silencing/overexpression experiments and 3´UTR 
luciferase reporter assays were based on two-tailed Student’s t-tests for averages 
comparison in paired samples. Data were analyzed by using Microsoft Excel (Microsoft 
Office, 2008 release) and are reported as mean ± standard error of the mean (SEM). P 
<.05 was considered significant. 
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RESULTS 
 
Gene expression profile of CD34+ cells from PMF patients 
We performed mRNA expression profiling in CD34+ cells from 42 PMF patients (n=23 
JAK2V617F-positive, n=19 wild-type JAK2) and 31 healthy donors (n=15 from the BM and 
n=16 from the PB). All microarray data (GEP and miEP) were submitted to the Gene 
Expression Omnibus repository (GEO; http://www.ncbi.nlm.nih.gov/geo) and can be 
downloaded as series GSE41812 and GSE53482. 
After data pre-processing, to explore the relationships between samples, we performed a 
principal component analysis (PCA). Figure 1A shows that the PMF samples clustered 
together and were clearly separated from both the BM and PB control samples. Of note, 
unsupervised analysis was unable to ungroup JAK2V617F and wild-type JAK2 patients. 
Next, using an analysis of variance (ANOVA)-based supervised approach for comparing 
PMF samples with both BM and PB controls, we identified 718 DEGs. Table S3 shows the 
100 most up- and downregulated genes.  
Array data confirmed the abnormal expression of several genes (i.e., WT1, NFE2, CXCR4, 
CD9) previously identified as deregulated in PMF CD34+ cells by our group in a different 
cohort of PMF patients24. Moreover, PMF samples exhibited increased levels of several 
putative cancer markers, such as ANGPT1, CEACAM8, and CP, previously reported to be 
associated with poor prognosis in hematological and solid neoplasms, as well as genes 
associated with BM fibrosis (LEPR, MMP9, and TIMP3) and aberrant migration (TM4SF1, 
RHOB, ARHGAP18, and MMP8). In addition, PMF samples showed a deregulated 
expression pattern of a number of transcription factors and chromatin remodelers involved 
in myeloid and MK commitment, either downregulated (i.e., JARID2, RUNX2, KLF3, and 
AFF3) or upregulated (i.e., FHL2, MAF, and IKZF2) (for a list of pertinent references, see 
Table S4). A selected list of DEGs chosen for their biological significance is presented in 
Table 1. 
To validate the array data, we designed a TaqMan low-density array containing 
63+GAPDH TaqMan gene expression assays (Table S5). The selection of genes was 
based on either the highest absolute fold change contrast and/or their putative role in PMF 
pathogenesis. TaqMan assays were carried out in an independent cohort of CD34+ cells 
from 10 PMF patients and 8 healthy subjects (n=4 BM, n=4 PB) and enabled validation of 
the expression of 50 out of 63 genes (79.4%) (Table S6). 
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miRNA expression profile of CD34+ cells from PMF patients 
To draw a comprehensive picture of miRNA deregulation and its relationship with 
differential gene expression in PMF cells, we performed miEP in the same sample set, 
using the Affymetrix miRNA 2.0 arrays. As already described for GEP, after an initial pre-
processing of data aimed at removing the noise, we performed a PCA to explore the 
relationships between samples. Figure 1B depicts the PCA graph, which shows the 
presence of a cluster of PMF samples that is clearly distinct from the PB and BM samples; 
moreover, PCA did not show any difference between mutated JAK2V617F and wild-type 
JAK2 patients, similar to the GEP PCA. 
Next, by using an ANOVA-based supervised approach as described in the Methods 
section, we selected 76 DEMs (Table S7). In particular, we found several upregulated 
miRNAs associated with hematological malignancies, or known as oncomiRs (i.e., miR-
155-5p, miR-21-5p, miR-29a-3p, and miRNAs belonging to the miR-17-92 cluster)25. By 
contrast, among the downregulated miRNAs, we found miR-378c, which is described as a 
tumor suppressor gene in gastric cancer26. Furthermore, overexpressed miRNAs 
previously identified as being involved in MK commitment were also found (i.e., miR-146b-
5p and miR-34a-5p)27. 
To validate the array data, we used TaqMan single microRNA assays to assess the 
expression of 46 DEMs, which were selected based on either their relatively high 
differential expression or their biological role in cancer-related processes or myeloid 
differentiation (Table S8). TaqMan assays were carried out in an independent cohort of 
CD34+ cells from 10 PMF patients and 8 healthy subjects (n=4 BM, n=4 PB) and 
confirmed the deregulated expression of 34 out of 46 miRNAs (73.9%) (Table S9). 
 
Validation of a gene set on granulocytes and serum from PMF patients 
Among the 50 validated genes described above, we selected a set of 7 genes (OLFM4, 
LCN2, LEPR, FGR, ANXA3, CEACAM8, and DEF1A) out of those most upregulated to 
validate their expression in granulocytes, which represent a more appropriate source for 
diagnostic/prognostic purposes. Using qRT-PCR, we observed that OLFM4, LCN2, LEPR, 
FGR, and ANXA3 mRNA levels were significantly increased in PMF granulocytes (n=32) 
compared to healthy controls (n=12) (Figure 2A), whereas CEACAM8 and DEF1A 
expression was not statistically modulated between the two groups (data not shown). 
Since OLFM4 and LCN2 genes encode for two secreted proteins, we assessed OLFM4 
and LCN2 protein levels in the serum of the same PMF patients (n=32) and healthy donors 
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(n=8) by means of an enzyme-linked immunosorbent assay (ELISA). As shown in Figure 
2B, the levels of OLFM4 and LCN2 secreted proteins were significantly higher in PMF 
patients than in healthy donors. Of note, the median concentration of OLFM4 serum 
protein was 5-fold higher in PMF patients than in controls. 
 
Validation of the selected miRNAs in the granulocytes from PMF patients 
Among the validated miRNAs in PMF CD34+ cells, we selected the 16 most upregulated 
ones (Table S9) to test their expression in the granulocytes from the same PMF patients 
(n=30) and healthy donors (n=8) previously used for mRNA expression validation. We 
demonstrated that the levels of miR-19a-3p, miR-335-5p, miR-379-5p, miR-376c-3p, miR-
487b-3p, and miR-494-3p were significantly increased in PMF granulocytes compared with 
controls, whereas miR-486-3p expression was significantly decreased in PMF 
granulocytes, in contrast to the results obtained in CD34+ cells (Figure 2C). The levels of 
the remaining miRNAs were not statistically modulated between PMF and controls (data 
not shown). 
 
GEP and miEP integrative analysis 
Since each miRNA can target many mRNAs while a single mRNA can be targeted by 
multiple miRNAs, we performed IA by means of IPA to untangle this combinatorial 
complexity. Based on IPA, we selected DEM-DEG pairs with an anti-correlated expression 
pattern. In particular, 56 out of the 76 DEMs have at least one anti-correlated target 
among DEGs, whereas 445 out of the 718 DEGs have at least one anti-correlated 
targeting DEM. 1167 anti-correlated miRNA-target pairs were finally generated. 
Among the interaction networks uncovered by IPA, we focused our attention on three of 
them because of their enrichment in genes and miRNAs involved in myeloproliferative 
disorders and/or in hematopoietic differentiation. Figure 3A shows several miRNAs that 
are highly expressed in PMF, such as miR-18a-5p, miR-29a-3p, miR-433-3p, miR-19a-3p, 
miR-155-5p, miR-195-5p, miR-200c-3p, and miR-152-3p, and their downregulated targets 
(BRWD1, JARID2, PHC3, and HMGB3) implicated in chromatin remodeling, a process 
severely impaired in MPNs. The second network (Figure 3B) displays several upregulated 
miRNAs involved in myeloid differentiation (miR-155-5p, miR-21-5p, miR-29a-3p)28 and 
their interactions with downregulated transcription factors, known as leukemic tumor 
suppressors (TLE4, MLL5, FOXO1) or myeloid commitment regulators (CEBPD, CEBPG, 
MAFF, TCF4, MXD1). 
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Finally, through IA we could identify a regulatory network gathering a high number of 
upregulated oncomiRs (i.e., miR-155-5p, miR-29a-3p, miR-92b-3p, miR-19a-3p, miR-18a-
5p) targeting anti-correlated mRNAs whose downregulation or deletion has been related to 
hematopoietic disorders. In particular, hypoallelic NR4A3 or CDC42 knockout in mice 
leads to a myeloproliferative disorder29,30, while JARID2 is a frequently deleted gene in 
leukemic transformation of chronic myeloid malignancies31; the other target HMGB3 is 
instead described as a regulator of self-renewal/differentiation balance in murine 
hematopoietic stem cells32 (Figure 3C). 
 
miRNA-mRNA interaction validation by luciferase reporter assays 
Because the network shown in Figure 3C contained the highest number of oncomiRs and 
targets involved in malignant hematopoiesis, it was selected to validate every putative 
miRNA/target pair by assessing 3´ untranslated region (UTR) luciferase activity upon 
miRNA overexpression; K562 cells were selected as in vitro system providing a 
hematopoietic background. As shown in Figure 4A, our data demonstrated that the 
following 3´UTR-miRNA interactions were statistically significant: JARID2 3′UTR- by miR-
152-3p, miR-195-5p, and miR-155-5p (further details on JARID2 3′UTR/miR-155-5p 
interaction are provided in the Supplemental Results); CDC42 3′UTR- by miR-29a-3p and 
miR-18a-5p; HMGB3 3′UTR- by miR-152-3p, miR-200c-3p, miR-433-3p, and miR-155-5p; 
NR4A3 3′UTR- by miR-335-5p and miR-92b-3p. Conversely, the interactions between the 
remaining miRNA-3´UTR target pairs were not confirmed. Figure 4B graphically 
recapitulates all the confirmed and non-confirmed interactions of the IA network previously 
shown. Figure 4C clearly shows that mutations in the miRNA binding site of 3'UTR targets 
prevented the decrease in luciferase reporter activity by miRNAs, which conversely occurs 
in their wild-type counterparts. Collectively, the luciferase assay data support the good 
predictive power by IA, as demonstrated by the 11/17 (64.7%) successful predictions for 
the selected network.  
 
Silencing of JARID2 in normal CD34+ cells  
Since the contribution of JARID2 to PMF pathogenesis has never been investigated, we 
performed RNAi-mediated gene silencing experiments on normal CD34+ cells. First, we 
optimized the CD34+ cell nucleofection protocol for the Amaxa 4D-Nucleofector™ System 
technology (see Supplemental Results). 
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CD34+ cells were transfected with a mixture of three Silencer Select siRNAs targeting 
JARID2 mRNA (Table S2) and with a non-targeting siRNA as a negative control 
(NegCTR). The expression level of JARID2 in control samples and JARID2-siRNA cells 
was assessed by qRT-PCR at 24 and 48 h after the last nucleofection (Figure 5A). 
Flow cytometric analysis of the CD41 MK marker performed on serum-free multilineage 
culture at day 8, 10, and 12 showed that JARID2 inhibition induces a significant increase 
in the MK fraction compared to the NegCTR sample (Figure 5B). Unilineage MK 
differentiation culture experiments further confirmed these results (Figure 5C). Flow 
cytometric analysis of granulocytic, mono-macrophagic, and erythrocyte differentiation 
markers did not highlight any significant modulation between JARID2-siRNA CD34+ cells 
and the NegCTR sample (data not shown). The methylcellulose assay indicated a 1.5-fold 
increase in the clonogenic efficiency of JARID2-siRNA CD34+ cells versus the NegCTR 
sample, whereas there was no significant difference in the percentage of erythroid and 
myeloid colonies (data not shown). 
Next, we examined the effect of JARID2 silencing on MK commitment by plating NegCTR 
and JARID2-siRNA CD34+ cells in a collagen-based serum-free semisolid culture medium 
that supports the growth of MK progenitors in vitro. The results, reported in Figure 5D, 
demonstrated that JARID2 silencing induces a remarkable increase in colony-forming unit-
megakaryocytes (CFU-MK) and a strong decrease of non-megakaryocyte colonies (CFU 
non-MK) compared to the NegCTR sample. Moreover, morphological evaluation of May–
Grünwald–Giemsa-stained (MGG-stained) cytospins of thrombopoietin-treated cells at day 
8 and 10 after the last nucleofection clearly displayed a considerable enrichment in MK 
precursors at different stages of maturation in JARID2-siRNA cells compared to NegCTR 
(Figure 5E). Finally, to better characterize the changes in gene expression induced by 
JARID2 gene silencing, we performed mRNA profiling in NegCTR and JARID2-siRNA 
CD34+ cells (see Supplemental Results and Figure S1). 
 
miR-155-5p overexpression and silencing in normal and PMF CD34+ cells 
Next, we asked whether any JARID2-targeting miRNA could reproduce its silencing effects 
on MK differentiation. Thus, we decided to overexpress miR-155-5p in normal CD34+ 
cells, because it was highlighted by the luciferase reporter assay as the strongest regulator 
of the JARID2 3´UTR (Figure 4A). Furthermore, a significant negative correlation was 
observed between miR-155-5p and JARID2 expression levels across the whole microarray 
dataset (r= −0.55, P=5.29×10-7) (Figure S2). 
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CD34+ cells were transfected either with miR-155-5p mimic or with Neg-mimic. By means 
of qRT-PCR, we observed that the JARID2 mRNA level was downregulated upon miR-
155-5p overexpression (RQ±SEM, 34.7±11.1, P < .05) at 24 and 48 h after the last 
nucleofection (Figure 6Ai). 
As observed for the JARID2 knockdown, miR-155-5p overexpression led to a significant 
increase of the percentage of CD41+ cells at day 10 and 12 after the last nucleofection in 
serum-free multi-lineage culture (Figure 6Aii). Similar results were obtained under 
unilineage MK differentiation culture conditions (Figure 6Aiii). Furthermore, the collagen-
based assay showed that miR-155-5p overexpression causes a significant increase in the 
CFU-MK percentage coupled with a strong decrease of non-MK colonies (Figure 6Aiv). 
Finally, the morphological analysis of MGG-stained cytospins showed a remarkable 
enrichment in MK precursors at different stages of maturation in miR-155-5p–
overexpressing cells compared to controls at day 10 and 12 after the last nucleofection 
(Figure 6Av). 
Furthermore, we aimed at assessing whether miR-155-5p downregulation in PMF CD34+ 
cells could reduce the expansion MK lineage. First, we evaluated JARID2 levels upon 
miR-155-5p silencing, observing a statistically significant increase at 24 and 48 h after the 
last nucleofection (Figure 6Bi). Strikingly, knockdown of miR-155-5p impaired the ability of 
PMF CD34+ cells to give rise to CD41+ cells, in both multi-lineage and MK unilineage 
cultures (Figure 6Bii-iii). Those observations were further confirmed by decrease of CFU-
MK colonies in collagen-based assays (Figure 6Biv) and by decrease of MK progenitors 
in MGG-stained cytospins (Figure 6Bv). 
 
Functional validation of the miR-155-5p/JARID2 axis in MK lineage expansion  
In order to demonstrate that miR-155-5p affects megakaryocytopoiesis by means of 
JARID2 modulation, we concurrently overexpressed JARID2 and miR-155-5p in normal 
CD34+ cells. To this aim, CB CD34+ cells were nucleofected twice with miR-155-5p or 
Neg-mimic and consecutively transduced with the retroviral vector expressing JARID2 
cDNA (LJARID2I∆N) or empty vector (LXI∆N) (see timing flowchart in Figure 7Ai and 
Supplemental Methods)33. To assess JARID2 expression, qRT-PCR was performed after 
NGFR+ cell purification (Figure 7Aii). As shown in Figure 7Aiii, the fraction of CD41+ 
cells in the MK unilineage culture decreased in miR-155-5p/LJARID2I∆N compared to 
miR-155-5p/LXI∆N cells at day 4, 7, and 11 post-purification. Moreover, the CFU-MK 
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assay results showed that JARID2 overexpression in miR-155-5p cells causes a significant 
decrease in the CFU-MK percentage compared to miR-155-5p/LXI∆N cells (Figure 7Aiv). 
Furthermore, to confirm that miR-155-5p driven megakaryopoiesis depends on JARID2 
mRNA levels, we simultaneusly silenced miR-155-5p and JARID2 in normal CD34+ cells 
(see timing flowchart in Figure 7Bi and Supplemental Methods). The expression level of 
JARID2 was assessed by qRT-PCR at 48 h after the last nucleofection (Figure 7Bii). Flow 
cytometric analysis of CD41 expression performed on the MK unilineage culture at day 8, 
10, and 12 after the last nucleofection showed a decrease in the MK fraction in miR-155-
5p-silenced cells compared to NegCTR/NegINH cells (Figure 7Biii). As expected, the 
simultaneous JARID2 knockdown could rescue the MK differentiation unbalance in miR-
155-5p silenced cells. In agreement with the flow cytometry data, the results of MK assay 
highlighted that the concurrent downregulation of miR-155-5p and JARID2 could prevent 
the impairment of MK differentiation observed in both independently silenced miR-155-5p 
and JARID2 samples (Figure 7Biv). 
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DISCUSSION 
In this study, we aimed at characterizing the role of miRNAs in PMF pathogenesis. To this 
end, we integrated GEP and miEP of PMF CD34+ cells, demonstrating how differentially 
expressed miRNAs affect the gene expression pattern in PMF cells. In particular, miRNA-
mRNA expression data integration led to the identification of several networks, one of 
which was further investigated in terms of interactions between miRNAs and the 3´UTRs 
of their putative targets. Finally, we demonstrated that the overexpression of miR-155-5p 
in normal CD34+ cells, as well as the silencing of its validated target JARID2, determines 
the expansion of the megakaryocytic lineage. Conversely, we showed that miR-155-5p 
inhibition in PMF CD34+ cells impaired the MK commitment. Overall, this work sheds light 
on the influence of deregulated miRNAs on gene expression regulation in PMF CD34+ 
cells and on their contribution to features typical of PMF, such as a hyperplastic 
megakaryopoiesis. In parallel, the assessment of the expression levels of several DEGs in 
PMF granulocytes highlighted a number of possible disease markers, which might 
eventually become relevant for target therapy approaches, such as membrane protein- 
and kinase-coding genes. 
Because miRNAs were recently demonstrated to be deregulated in MPN cells15-17, interest 
of their involvement in pathogenetic mechanisms is progressively growing. However, most 
of the miRNA and mRNA expression studies performed to date have been conducted 
using terminally differentiated hematopoietic cells, namely granulocytes or 
megakaryocytes15,16,34,35. Since MPNs are considered to arise from the hematopoietic 
stem cell compartment36, understanding of the pathogenetic molecular mechanisms 
should best be assessed by studying CD34+ cells. So far, only two studies have reported 
data on miRNA expression profiling in a very small number of MPN CD34+ samples17,18, 
and no integrated miRNA-mRNA expression analysis was available until now. Here, we 
provide the results of an extensive study that profiled both gene and miRNA expression in 
the same CD34+ cell sample from 42 PMF patients.  
GEP and miEP analysis showed that PMF CD34+ cells present a different expression 
pattern compared to BM and unmobilized PB CD34+ cells; of note, PCA was unable to 
separate PMF patients according to JAK2 mutational status (Figures 1A and B). 
Differential expression analysis enabled the identification of several deregulated miRNAs 
and mRNAs suitable as biomarkers or as putative molecular targets for diagnostic or 
prognostic purposes. Therefore, the most upregulated genes and miRNAs were monitored 
on PMF granulocytes because they could represent a more suitable cell source for clinical 
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praxis, whereas secreted protein levels were assessed in the patients’ sera. We identified 
a set of five genes (i.e., LCN2, OLFM4, ANXA3, FGR, and LEPR) (Figure 2A) and six 
miRNAs (i.e., miR-19a-3p, miR-335-5p, miR-376c-3p, miR-379-5p, miR-487b-3p, and 
miR-494-3p) (Figure 2B) whose expression levels are aberrant in PMF granulocytes as 
well as in CD34+ cells. Evidence in PMF of a higher mRNA expression of the leptin 
receptor (LEPR), previously reported in AML37, as well as of Src kinase FGR38, could also 
be useful to drive the future design of targeted drugs. Of note, LEPR and Src kinase 
inhibitors are already being used in preclinical or clinical trials39,40. In addition, we 
demonstrated that OLFM4 and LCN2 secreted protein levels could be considered as PMF 
biomarkers, since they were significantly high in patients’ sera compared to those of 
healthy controls. Strikingly, more than 80% of the PMF patients presented with higher 
OLFM4 protein levels compared to all the evaluated controls.  
The present study has mainly provided information about the molecular mechanisms 
underlying PMF pathogenesis. Indeed, data analysis clearly showed that several genes 
involved in adhesion or migration processes (TM4SF1, RHOB, ARHGAP18, and MMP8) 
as well as fibrogenic potential (LEPR, MMP9, and TIMP3) are deregulated in PMF CD34+ 
cells. Interestingly, regulators of megakaryocytic commitment were also upregulated (i.e., 
NFE-2, MEF2C, miR-146b-5p, miR-34a-5p). Furthermore, we found an increased 
expression of genes or miRNAs with oncogenic potential, i.e., CEACAM8, ANGPT1, miR-
29a-3p, and miRNAs belonging to the miR-17-92 cluster 25,41 (Table S4). 
Since one of the main mechanisms through which miRNAs act is degradation of specific 
targets42, miRNAs and their targets are expected to display anti-correlated expression. 
Hence, we performed IA to select more reliable interactions among those predicted in 
silico. As chromatin remodeling is one of the main processes involved in PMF 
pathogenesis, we determined whether a DEM could affect this pathway. Figure 3A shows 
that chromatin remodeler genes such as PHC3 and HMGB3 could be downregulated by a 
network of upregulated targeting miRNAs, i.e., miR-18a-5p, miR-433-3p, miR-195-5p, 
miR-200c-3p, and miR-152-3p. We also observed that low expression of different 
hematopoietic transcription factors as well as leukemia suppressors (i.e., CEBP, FOXO1, 
MLL5) is, at least in part, caused by several highly expressed oncomiRs such as miR-21-
5p and miR-29a-3p, as depicted in Figure 3B. Finally, a single regulatory network 
collecting the highest number of oncomiRs and target genes involved in malignant 
hematopoiesis is shown in Figure 3C. Of note, by means of 3´UTR luciferase reporter 
assays, we were able to confirm 11/17 (64.7%) putative interactions for the above-
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mentioned network, highlighting the good predictive power of IA in identifying true miRNA-
target interactions (Figure 4). Specifically, the upregulation of several targeting miRNAs 
explains the negative regulation of genes like CDC42 and NR4A3, whose downregulation 
leads to myeloproliferative disorders in murine models29,30, as well as HMGB3, which 
codes for a regulator of the self-renewal/differentiation balance in murine hematopoietic 
stem cells32. Moreover, upregulated miR-155-5p, miR-195-5p, and miR-152-3p share the 
experimentally observed target JARID2, a chromatin remodeler that is a member of the 
Jumonji family of transcription factors belonging to the polycomb repressive complex 2 
(PRC2)43. Of note, Puda and colleagues demonstrated that JARID2 is frequently deleted 
in leukemic transformation of chronic myeloid malignancies31. However, although the 
function of JARID2 in hematopoiesis has been already partially unraveled in mouse 
embryo development studies, there are no data about its role in human primary 
hematopoietic CD34+ cells44. Thus, we decided to investigate the effect of JARID2 
downregulation in hematopoiesis by means of RNAi-mediated silencing in human normal 
CD34+ cells. Our findings support the contributing role of JARID2 deficiency in the 
expansion of the MK lineage both in liquid and in semisolid culture, as shown in Figure 5. 
Because the most effective miRNA in downregulating JARID2 3´UTR-luciferase activity 
was miR-155-5p, whose enforced expression causes a myeloproliferative disorder in 
mice45, we accordingly overexpressed this miRNA in hematopoietic CD34+ cells. Here, we 
demonstrated that miR-155-5p overexpression downregulates JARID2 mRNA, thus 
supporting the expansion of the MK compartment (Figure 6A). In parallel, miRNA 
inhibition in PMF CD34+ cells clearly showed that miR-155-5p may play an important role 
in the increased megakaryopoiesis observed in PMF patients (Figure 6B). Finally, the 
restoration of JARID2 expression level in miR-155-5p-overexpressing CD34+ cells 
impaired the expansion of MK lineage induced by miR-155-5p (Figure 7A); this unbalance 
could be prevented by simultaneusly silencing JARID2 and miR-155-5p as well, thus 
definitively demonstrating that miR155-5p affects megakaryopoiesis via JARID2 
modulation (Figure 7B). Overall, this interaction could explain the MK hyperplasia 
observed in BM biopsies of PMF patients19 and the high proliferative potential of MKs 
derived from PMF CD34+ cells reported in studies in vitro46. Moreover, the analysis of 
miR-155-5p and JARID2 mRNA levels in ET CD34+ cells revealed that this regulatory axis 
specifically works in PMF CD34+ cells (see Figure S3 and Supplemental Results). 
Taken together, integration of GEP and miEP uncovered regulatory networks in which 
aberrantly expressed miRNAs and genes interact, thereby elucidating some of the 
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pathogenetic characteristics of PMF. Finally, integrative analysis has proven to be a good 
approach for identifying reliable mRNA/miRNA interactions that could contribute to PMF 
pathogenesis, such as the JARID2-miR-155-5p axis, which is involved in hyperplastic 
megakaryopoiesis. 
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Table 1. DEGs selected by biological significance 
Gene 
Symbol 
Gene Ontology 
function Notes FC 
ANGPT1 Secreted protein Overexpressed in AML, CML, MDSs 3,1 
ANXA3 
Cytoplasmatic 
protein Negative prognostic factor for prostate cancer 10,4 
ARHGAP18 
Cytoplasmatic 
protein Involved in cell spreading and motility 3,0 
CD9 Membrane protein 
Involved in platelet activation and aggregation; involved in 
BM remodeling in PMF 2,2 
CEACAM8 Membrane protein Overexpressed in imatinib resistant CML cells 5,5 
CP Enzyme 
Overexpressed in AML; negative prognostic factor for 
renal carcinoma 2,6 
DEFA1 Secreted protein 
Overexpressed in imatinib resistant CML cells; biomarker 
for diagnosis of CRCA 60,2 
FGR Kinase Involved in cell migration 1,9 
FHL2 
Transcription 
factor Promotes myeloid proliferation; overexpressed in AML 2,7 
IDH1 
Cytoplasmatic 
protein Mutated in MPNs 2,4 
IFI27 Membrane protein Involved in defense and immunity 2,4 
IFIH1 
Cytoplasmatic 
protein Involved in defense and immunity 2,3 
IKZF2 
Transcription 
factor Overexpressed in in Hodgkin Lymphoma and ALL 3,6 
ITGB3 Membrane protein Involved in platelet activation and aggregation 2,5 
LCN2 Secreted protein 
Expression induced by BCR-ABL protein; negative 
prognostic factor for breast cancer 7,0 
LEPR Membrane protein Overexpressed in AML and PMF; involved in fibrosis 9,7 
MAF 
Transcription 
factor Negative prognostic factor for MM 8,0 
MEF2C 
Transcription 
factor Involved in MKs differentiation 2,3 
MMP9 
Extracellular matrix 
protein Involved in the development of fibrosis 3,8 
MYC 
Transcription 
factor Involved in MKs differentiation, cancer marker 2,8 
NFE2 
Transcription 
Involved in MKs differentiation; overexpressed in PMF 2,0 
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factor 
OLFM4 Secreted protein 
Negative prognostic factor for colorectal, breast and lung 
cancer 3,5 
PF4 Secreted protein Involved in platelet activation and aggregation 3,4 
PIM1 
Transcription 
factor Overexpressed in PMF 2,6 
RHOB 
Cytoplasmatic 
protein Involved in cell spreading and motility 3,7 
TIMP3 
Extracellular matrix 
protein Involved in the development of fibrosis 4,0 
TM4SF1 Membrane protein Involved in cell spreading and motility 4,4 
VWF Secreted protein 
Highly expressed by early MKs, involved in platelet 
adhesion 4,4 
WT1 
Transcription 
factor 
Negative prognostic factor in AML; associated with high 
severity score in PMF 2,0 
AFF3 
Transcription 
factor 
Fusion with MLL gene in ALL and with RUNX1 gene, 
partner of MLL -2,2 
ARHGEF7 
Cytoplasmatic 
protein Involved in cell migration, attachment and cell spreading -2,2 
ARID4A Nuclear protein 
Involved in chromatin remodeling; K/O mice develop 
myelofibrosis -2,3 
BRWD1 Nuclear protein Involved in chromatin remodeling -1,8 
CDC42 
Cytoplasmatic 
protein 
Cdc42-deficient mice developed a fatal myeloproliferative 
disorder -4,9 
CEBPD 
Transcription 
factor Myeloid commitment regulator -2,2 
CEBPG 
Transcription 
factor Myeloid commitment regulator -2,5 
CXCR4 Membrane protein Involved in bone marrow homing -2,5 
EIF2AK3 Kinase 
The ablation in tumor cells resultes in accumulation of 
ROS  -3,0 
FOXO1 
Transcription 
factor 
Involved in OXS response; negative prognostic factor for 
AML -2,3 
HMGB3 Nuclear protein 
Involved in chromatin remodeling; required for the proper 
balance between HSC self-renewal and differentiation -2,5 
IRF4 
Transcription 
factor Downregulated in CML -2,7 
IRF8 
Transcription 
factor Downregulated in CML -6,4 
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JARID2 Nuclear protein Involved in chromatin remodeling and in AML progression -2,5 
KLF3 
Transcription 
factor 
Downregulated in AML; K/O mice display abnormalities in 
hematopoiesis -3,6 
MAFF 
Transcription 
factor Myeloid commitment regulator -2,0 
MEF2D 
Transcription 
factor 
Involved in myogenic differentiation; fusion with DAZAP1 
gene in ALL -2,7 
MLL5 
Transcription 
factor Frequently deleted in human myeloid malignancies -2,7 
MXD1 
Transcription 
factor 
Involved in regulation of cell proliferation; antagonizes 
MYC gene -3,4 
NR4A3 Nuclear protein  
Involved in chromatin remodeling; hypoallelic mice display 
MDS/MPNs feautures -2,4 
NUP98 
Transcription 
factor 
Involved in fusions with different partner genes in patients 
with hematopoietic malignancies -2,5 
PHC3 Nuclear protein Component of polycomb repressive complex -2,1 
PURB Nuclear protein Deleted in MDS and AML -2,5 
RUNX2 
Transcription 
factor 
Involved in hematopoietic and osteogenic lineages 
differentiation -2,1 
SF3B1 Nuclear protein Mutated in MDS and in MDS/MPNs -2,0 
SMAD7 
Transcription 
factor Involved in fibrosis; downregulated in MDSs  -7,2 
TCF4 
Transcription 
factor Myeloid commitment regulator -2,4 
TLE4 
Transcription 
factor Deleted in AML -2,2 
TP53INP1 Nuclear protein 
Loss of expression in several cancers; inactivation 
correlates with increased cell migration  -2,5 
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDSs, myelodysplastic 
syndromes; BM, bone marrow; PMF, primary myelofibrosis; ALL, acute lymphoblastic leukemia; CRCA, 
colorectal cancer; MPNs, myeloproliferative neoplasms; MM, multiple myeloma; MKs, megakaryocytes; K/O, 
knock/out; ROS, reactive oxygen species; OXS, oxidative stress; HSC, hematopoietic stem cell; MDS/MPNs, 
myelodysplastic/myeloproliferative neoplasms 
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FIGURE LEGENDS 
 
Figure 1. Principal component analysis (PCA) of gene and microRNA expression 
microarray data. (A) The PCA graph of global gene expression data and (B) PCA graph 
of global miRNA expression data were computed using Partek GS, version 6.6; bone 
marrow (BM) control samples are shown as red spheres; peripheral blood (PB) control 
samples are shown as blue spheres; primary myelofibrosis (PMF) samples are shown in 
green. PMF JAK2 wild-type samples are shown as pyramids, while PMF JAK2V617F 
samples are shown as prisms. 
 
Figure 2. Validation of the selected genes and miRNAs in granulocytes and plasma 
from primary myelofibrosis (PMF) patients. (A) Expression of the seven selected genes 
in granulocytes from PMF patients and healthy donors. Gene expression levels were 
measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
starting from granulocyte total RNA and were expressed as relative quantity (RQ). Boxes 
represent the interquartile range that contains 50% of the subjects, the horizontal line in 
the box marks the median, and the bars show the range of values. Data are representative 
of 32 PMF and 12 control (CTR) samples. (B) Serum levels of two secreted proteins 
(LCN2 and OLFM4) in PMF patients and healthy donors. Protein levels were measured by 
enzyme-linked immunosorbent assay (ELISA) and were expressed as ng/mL. Boxes 
represent the interquartile range that contains 50% of the subjects, the horizontal line in 
the box marks the median, and the bars show the range of values. Data are representative 
of 30 PMF and 8 CTR samples. (C) Expression levels of the eight selected miRNAs in 
granulocytes from PMF patients and healthy donors. The miRNA expression levels were 
measured by qRT-PCR starting from granulocyte total RNA and were expressed as RQ. 
Boxes represent the interquartile range that contains 50% of the subjects, the horizontal 
line in the box marks the median, and the bars show the range of values. Data are 
representative of 32 PMF and 12 CTR samples. *, P < .05 vs. CTR.  
 
Figure 3. Regulatory networks of mRNA-miRNA interactions built through Ingenuity 
Pathway Analysis (IPA). Visualization of the regulatory networks enriched for: (A) 
chromatin remodeling genes, (B) myeloid transcription factors, and (C) myeloproliferative 
disorder-related genes. Red filling means upregulation, while green filling indicates 
downregulation. 
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Figure 4. Validation of 3´UTR–miRNA interactions. (A) Normalized luciferase activity of 
K562 cells nucleofected with the indicated miRNA mimics and 3’untranslated region 
(3´UTR) luciferase reporter vectors. Firefly luciferase activity was measured 48 h after 
nucleofection and normalized to Renilla luciferase activity. Values are reported as mean ± 
standard error of the mean (SEM); *, P < .05 versus miRNA mimic negative control (Neg-
mimic). Results come from three independent experiments performed in duplicate. (B) 
Graphical representation of mRNA-miRNA interactions validated by means of 3´UTR 
luciferase reporter assays. Solid lines (validated interactions); dashed lines (not validated 
interactions). (C) Results of the luciferase reporter assays performed with wild type and 
mutant 3'UTR. Assays were carried out only for the 3'UTR-miRNA interactions previously 
validated (see panel A). Each bar represents the luciferase activity upon miRNA 
overexpression normalized on the value of the same 3'UTR luciferase vector upon Neg-
mimic transfection. Values are reported as mean ± SEM; *, P < .05 versus mutant 3'UTR. 
Results come from three independent experiments performed in duplicate.  
 
Figure 5. Effect of JARID2 silencing on normal CD34+ cell differentiation. (A) 
Expression levels of JARID2 at 24 and 48 h after the last nucleofection were measured by 
qRT-PCR and data are reported as RQ. (B–C) Results of the statistical analysis on the 
percentage of CD41+ cells performed by flow cytometry at day 5, 8, 10, and 12 after the 
last nucleofection on serum-free multilineage and megakaryocyte (MK) unilineage 
cultures. (D) Results of the statistical analysis of collagen-based clonogenic assay. The 
cells were plated 24 h after the last nucleofection and scored after 12 days. (E) 
Morphological analysis of negative control (NegCTR) (i–ii) and JARID2- short interfering 
RNA (JARID2-siRNA) (iii–iv) samples after May–Grünwald–Giemsa staining at day 8 and 
10 of MK unilineage culture after the last nucleofection in a representative experiment. 
Magnification, ×1000. Values are reported as mean ± standard error of the mean (SEM). 
**, P < .01 versus NegCTR; *, P < .05 versus NegCTR. The results come from five 
independent experiments. Abbreviations: NegCTR, siRNA negative control; siRNA, small 
interfering RNA; h, hours; CFU, colony-forming unit. 
 
Figure 6. Transfection of miR155-5p mimic and inhibitor in normal and PMF CD34+ 
cells. (A) Effect of miR155-5p mimic transfection on normal CD34+ cell differentiation. (i) 
Expression levels of JARID2 at 24 and 48 h after the last nucleofection, measured by qRT-
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PCR and reported as RQ. (ii-iii) Results of statistical analysis on the percentage of CD41+ 
cells performed by flow cytometry at day 5, 8, 10, and 12 after the last nucleofection on 
serum-free multilineage and MK unilineage cultures. (iv) Results of the statistical analysis 
of the collagen-based clonogenic assay. The cells were plated 24 h after the last 
nucleofection and scored after 12 d. (v) Morphological analysis of Neg-mimic and miR-
155-5p nucleofected cells after May–Grünwald–Giemsa staining at days 8 and 10 of MK 
unilineage serum-free liquid culture after the last nucleofection in a representative 
experiment. Magnification ×1000. Values are reported as mean ±  standard error of the 
mean (SEM). **, P < .01 versus Neg-mimic; *, P < .05 versus Neg-mimic. The results 
come from five independent experiments. (B) Effect of miR155-5p downregulation in PMF 
CD34+ cells. (i) Expression levels of JARID2 in PMF CD34+ cells at 24 and 48 h after the 
last nucleofection of miR-155-5p inhibitor. The JARID2 expression was measured by qRT-
PCR and data are reported as RQ. (ii-iii) Percentage of viable CD41+ cells assessed by 
flow cytometry at day 5, 8, and 10 after the last nucleofection on serum-free multilineage 
and MK unilineage cultures. (iv) Results of the statistical analysis of the collagen-based 
clonogenic assay. The cells were plated 24 h after the last nucleofection and scored after 
12 d. (v) Morphological analysis of negative control inhibitor (NegINH) and miR-155-5p 
inhibitor treated cells after May–Grünwald–Giemsa staining at days 8 and 10 of MK 
unilineage serum-free liquid culture after the last nucleofection in a representative 
experiment. Magnification ×1000. Values are reported as mean ± SEM. **, P < .01 versus 
Neg-INH; *, P < .05 versus Neg-INH. The results come from four independent 
experiments. Abbreviations: Neg-mimic, miRNA mimic Negative Control; h, hours; CFU, 
colony-forming unit; Neg-INH, miRNA inhibitor Negative Control. 
 
Figure 7. Simultaneous overexpression or inhibition of JARID2 and miR-155-5p in 
normal CD34+ cells. (A) Rescue of JARID2 expression in miR-155-5p overexpressing 
cells. (i) Flowchart listing the experiment timing (expressed in days) after NGFR+ cell 
purification. (ii) Expression levels of JARID2 in CB CD34+ cells after NGFR+ cells 
purification. The JARID2 expression was measured by qRT-PCR and data are reported as 
RQ. (iii) Percentage of viable CD41+ cells in the MK unilineage culture assessed by flow 
cytometry at day 4, 7, and 11 after NGFR+ cell purification. (iv) Results of the statistical 
analysis of the collagen-based clonogenic assay. The cells were plated 24 h after NGFR+ 
cell purification and scored after 12 d. Values are reported as mean ± standard error of the 
mean (SEM). **, P < .01; *, P < .05. The results come from three independent 
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experiments. (B) Simultaneous downregulation of JARID2 and miR155-5p in CB CD34+ 
cells. (i) Flowchart reporting the experiment timing (expressed in days) after the last 
nucleofection. (ii) Expression levels of JARID2 in CB CD34+ cells at 48 h after the last 
nucleofection. The JARID2 expression was measured by qRT-PCR and data are reported 
as RQ. (iii) Percentage of viable CD41+ cells in the MK unilineage culture assessed by 
flow cytometry at day 8, 10, and 12 after the last nucleofection. (iv) Results of the 
statistical analysis of the collagen-based clonogenic assay. The cells were plated 24 h 
after the last nucleofection and scored after 12 d. Values are reported as mean ±  SEM. **, 
P < .01; *, P < .05. The results come from three independent experiments. Abbreviations: 
Neg-mimic, miRNA mimic Negative Control; h, hours; CFU, colony-forming unit; NegCTR, 
siRNA negative control; NegINH, miRNA inhibitor Negative Control. 
 
 







